Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab;Schwerer verlauf einer miliartuberkulose bei einem 34-jährigen patienten mit colitis ulcerosa und hiv-Infektion unter einer TNF-a-Antikörper-Therapie

Medizinische Klinik

Volumn 105, Issue 4, 2010, Pages 314-318

  Zeitz, Jonas ^a   Huber, Milo ^a   Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anti TNF a; HIV; Infliximab; Tuberculosis; Ulcerative colitis

Indexed keywords

INFLIXIMAB; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ANEMIA; ARTICLE; CASE REPORT; DISEASE SEVERITY; FATALITY; FEVER; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG INFILTRATE; LUNG INSUFFICIENCY; LYMPHOCYTOPENIA; MALE; MILIARY TUBERCULOSIS; NEUTROPENIA; PLEURA EFFUSION; THROMBOCYTOPENIA; ULCERATIVE COLITIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COLITIS, ULCERATIVE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG COMBINATION; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; PATHOLOGY; TUBERCULOSIS, MILIARY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; COLITIS, ULCERATIVE; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HUMANS; MALE; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS, MILIARY;

EID: 77954630913     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-010-1046-2     Document Type: Article

References (22)

1. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998; 2:443-450
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359: 1541-1549
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035
4. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-238
5. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357: 239-250 (Pubitemid 47080388)
6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885
7. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353: 2462-2476 (Pubitemid 41770166)
9. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009; 22:403-409
10. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345: 1098-1104
11. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60: 1884-1894
12. Shale MJ, Seow CH, Coffin CS, et al. Review article: Chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:20-34.
13. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41:Suppl 3:S199-203.
14. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-152
15. Pai M, Zwerling A,Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-184
16. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for antiTNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907-913
17. Ligue Pulmonaire Suisse. Manuel de la tuberculose, 2ème édn. Berne: Ligue Pulmonaire Suisse, 2007 (http://www.tbinfo.ch).
18. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007; 137:620-622
19. Bourikas LA, Kourbeti IS, Koutsopoulos AV, et al. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 2008;57:425.
20. Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008;8: 100-103
21. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008;67:710-712
22. Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007;34:1353-1355